Virtual Overdose Response for People Who Use Opioids Alone: Protocol for a Feasibility and Clinical Trial Study

Sean Kristina Bristowe, Sumantra Monty Ghosh, Michael Trew, Canadian Mental Health Association - Calgary Region, Katherine Rittenbach, Sean Kristina Bristowe, Sumantra Monty Ghosh, Michael Trew, Canadian Mental Health Association - Calgary Region, Katherine Rittenbach

Abstract

Background: A recent quarterly report released by Alberta Health reports that on average 2.5 Albertans die every day from accidental overdose deaths, and that between April 1, 2020, and June 30, 2020, the province lost a total of 301 people. In Canada, between January 2016 and March 2020, a total of 16,364 people died due to opioid-related overdose. The World Health Organization reports that 70% of the 0.5 million deaths worldwide caused by drugs are related to opioid overdose. Although supervised consumption sites or safe injection sites have been shown to be effective in reducing the harms associated with the use of illicit substances and increasing uptake of addiction treatment and other health services, there is still significant stigma associated with them, and it is unlikely that all of the people who would benefit from supervised consumption service will ever access a site.

Objective: To help prevent deaths in populations that cannot or will not access physical safer consumption services in Alberta, we propose to provide virtual (telephone-based) overdose response services, staffed by people with lived experience.The primary outcome for this study is uptake of the service as measured by the number of calls to the service. Secondary outcomes will include patterns of use of the phone line (days of the week and time of calls) and outcomes from the calls (number of emergency medical services dispatches for overdoses from the service and the results of those dispatches).

Methods: This phase 1 clinical study is set to officially launch in early May 2020. The service will be available to up to 15 participants who self-disclose as using opioids unobserved and have given informed consent for both data collection and interviews. This group will have access to a toll-free telephone number and be invited to call when they plan to use opioids alone.

Results: The analysis will include mixed methods. To improve the design of the service and ensure safety of all involved, quantitative data will be collected on phone calls and participant health care usage, while qualitative data will be collected from both participants and virtual overdose response operators.

Conclusions: This clinical trial aims to test the feasibility of a service that provides virtual overdose response in order to help prevent deaths in populations that cannot or will not access physical supervised consumption services in Alberta.

Trial registration: ClinicalTrials.gov NCT04391192; https://www.clinicaltrials.gov/ct2/show/NCT04391192.

International registered report identifier (irrid): DERR1-10.2196/20183.

Keywords: harm reduction; opioid crisis; overdose response; peers; people with lived experience.

Conflict of interest statement

Conflicts of Interest: None declared.

©Sean Kristina Bristowe, Sumantra Monty Ghosh, Michael Trew, Canadian Mental Health Association - Calgary Region, Katherine Rittenbach. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.05.2021.

References

    1. Opioid-related harms in Canada. Health Canada. 2020. Sep, [2020-05-20].
    1. Necyk C, Cor K, Mazzuca A, Meleshko L. An evaluation of Alberta pharmacists' practices, views and confidence regarding prescription drug abuse and addiction within their practice setting. Can Pharm J (Ott) 2019 Aug 13;152(6):376–387. doi: 10.1177/1715163519865914.
    1. Government of Alberta Opioid response surveillance report Q2 2020. Alberta Health. 2020. Sep, [2020-10-01]. .
    1. Opioid overdose fact sheet. World Health Organization. [2020-08-28]. .
    1. Canadian Institute for Health Information Pan-Canadian trends in the prescribing of opioids, 2012 to 2016. CIHI. 2017. [2020-05-01]. .
    1. Government of Alberta Opioids and substance misuse: Alberta report, 2018 Q1. Alberta Health. 2018. [2020-03-01]. .
    1. Hadland SE, Beletsky L. Tighter prescribing regulations drive illicit opioid sales. BMJ. 2018 Jun 13;361:k2480. doi: 10.1136/bmj.k2480.
    1. Martin J, Cunliffe J, Décary-Hétu David, Aldridge J. Effect of restricting the legal supply of prescription opioids on buying through online illicit marketplaces: interrupted time series analysis. BMJ. 2018 Jun 13;361:k2270. doi: 10.1136/bmj.k2270.
    1. Drug checking reveals more than half of all substances on the street not what expected. British Columbia Centre on Substance Use. 2018. May 17, [2020-05-01]. .
    1. Government of Alberta Minister's opioid emergency response commission. Alberta Health. 2018. [2020-05-01]. .
    1. Potier C, Laprévote Vincent, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014 Dec 01;145:48–68. doi: 10.1016/j.drugalcdep.2014.10.012.
    1. Kennedy MC, Karamouzian M, Kerr T. Public health and public order outcomes associated with supervised drug consumption facilities: a systematic review. Curr HIV/AIDS Rep. 2017 Oct 5;14(5):161–183. doi: 10.1007/s11904-017-0363-y.
    1. Merali F. PCs 'playing politics with people's lives' on injection sites, drug policy experts warns. CBC News. 2018. Aug 04, [2020-05-01]. .
    1. Williams CT, Metzger DS. Race and distance effects on regular syringe exchange program use and injection risks: a geobehavioral analysis. Am J Public Health. 2010 Jun;100(6):1068–1074. doi: 10.2105/ajph.2008.158337.
    1. Marshall BD, Milloy M, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. The Lancet. 2011 Apr;377(9775):1429–1437. doi: 10.1016/s0140-6736(10)62353-7.
    1. Enns EA, Zaric GS, Strike CJ, Jairam JA, Kolla G, Bayoumi AM. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada. Addiction. 2016 Mar 30;111(3):475–89. doi: 10.1111/add.13195.
    1. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ. 2008 Nov 18;179(11):1143–51. doi: 10.1503/cmaj.080808.
    1. Supporting people who use substances in shelter settings during the COVID-19 pandemic. CRISM. 2020. May 17, [2020-05-17]. .
    1. Bluthenthal RN, Simpson K, Ceasar RC, Zhao J, Wenger L, Kral AH. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. Drug Alcohol Depend. 2020 Jun 01;211:107932. doi: 10.1016/j.drugalcdep.2020.107932.
    1. Eibl JK, Gauthier G, Pellegrini D, Daiter J, Varenbut M, Hogenbirk JC, Marsh DC. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 2017 Jul 01;176:133–138. doi: 10.1016/j.drugalcdep.2017.01.048.
    1. Gates P. The effectiveness of helplines for the treatment of alcohol and illicit substance use. J Telemed Telecare. 2014 Oct 20;21(1):18–28. doi: 10.1177/1357633x14555643.
    1. Provincial Health Services Authority New Lifeguard app launched to help prevent overdoses. Provincial Health Services Authority. [2020-05-20]. .
    1. Bains C. Vancouver co-op develops tech aimed at helping prevent overdoses. Globe and Mail. 2018. Sep 19, [2020-05-01].
    1. Wells J. New hotline for opioid users aimed at reducing overdose deaths. The Spectator Report. 2020. Jan, [2020-05-01]. .
    1. Health Information Act. Government of Alberta. [2020-04-30]. .

Source: PubMed

3
Prenumerera